CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ¾ÈÈñÁ¤
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : »êºÎÀΰúº´¸®, ³­¼Òº´¸®, À¯¹æº´¸®, ºÐÀÚº´¸®
  • Á÷ À§: ±³¼ö
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

µî·Ï

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ ´Ù¿î·Îµå
16 ±¹³» Kwon AY, Kim GI, Jeong JY, Song JY, Kwack KB, Lee C, Kang HY, Kim TH, Heo JH, An HJ. VAV3 Overexpressed in Cancer Stem Cells Is a Poor Prognostic Indicator in Ovarian Cancer Patients. Stem Cells Dev. 2015 Jul 1;24(13):1521-35 (SCI, IF= 3.72)  
15 ±¹³» Kim TH, Song JY, Park H, Jeong JY, Kwon AY, Heo JH, Kang H, Kim G, An HJ. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma. Cancer letters 2015 Jan 28 ;356(2):937-45 (SCI, IF=5.016)  
14 ±¹³» Park H, Lee MJ, Jeong JY, Choi MC, Jung SG, Joo HD, Lee C, An HJ. Dysregulated MicroRNA Expression in Adenocarcinoma of the Uterine Cervix: Clinical Impact of miR-363-3p. Gynecologic oncology 2014 Dec ;135(3):565-72 (SCI, IF=3.687)  
13 ±¹³» Lee H, Kim KR, Cho NH, Hong SR, Jeong H, Kwon SY, Park KH, An HJ, Kim TH, Kim I, Yoon HK, Suh KS, Min KO, Choi HJ, Park JY, Yoo CW, Lee YS, Lee HJ, Lee WS, Park CS, Lee Y. MicroRNA expression profiling and Notch1 and Notch2 expression in minimal deviation adenocarcinoma of uterine cervix. World Journal of Surgical Oncology 2014 Nov 8 ;12:334 (SCI, IF=1.2)  
12 ±¹³» Kim Rj, Bae E, Hong YK, Hong JY, Kim NK, Ahn HJ, Oh JJ, Park DS. PTEN Loss-Mediated Akt Activation Increases the Properties of Cancer Stem-Like Cell Populations in Prostate Cancer. Oncology 2014 Oct 1 ;37(5):270-279 (SCI, IF=2.613)  
11 ±¹³» Kang KW, Lee MJ, Song JA, Jeong JY, Kim YK, Lee C, Kim TH, Kwak KB, Kim OJ, An HJ, Overexpression of goosecoid homeobox is associated with chemoresistance and poor prognosis in ovarian carcinoma. Oncology reports 2014 Jul; 32(1): 189-198 (SCI, IF=2.191)  
10 ±¹³» Park SH, Song JY, Kim YK, Heo JH, Kang H, Kim G, An HJ, Kim TH. Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells. International journal of oncology 2014 Mar; 44(3): 637-46 (SCI, IF=2.773)  
9 ±¹³» Huh JH, Kim TH, Kim K, Song JA, Jung YJ, Jeong JY, Lee MJ, Kim YK, Lee DH, An HJ. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer 2013 Jul 23;109(2):452-61. (SCI, IF=5.1)  
8 ±¹³» Jeong JY, Kim KS, Moon JS, Song JA, Choi SH, Kim KI, Kim TH, An HJ. Targeted inhibition of phosphatidyl inositol-3-kinase p110¥â, but not p110¥á, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers. Apoptosis. 2013 Apr;18(4):509-20 (SCI, IF=3.7)  
7 ±¹³» Park YT, Jeong JY, Lee MJ, Kim KI, Kim TH, Kwon YD, Lee C, Kim OJ, An HJ. MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance. J Ovarian Res. 2013 Mar 22;6(1):18(SCIE, IF=2.87)  
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729